| Description | Oxaceprol (N-Acetyl-L-hydroxyproline) is an established therapeutic agent for osteoarthritis. |
| In vivo | Oxaceprol, an established therapeutic agent for osteoarthritis, had no effect on macrophage prostaglandin E2 release in vitro and inhibited carrageenan paw oedema at high doses (18-150 mg/kg p.o.).?In the same dose range, oxaceprol was comparable to indomethacin (3 mg/kg p.o.) as an inhibitor of yeast hyperalgaesia and at 6-50 mg/kg/day p.o. had a mild, variable inhibitory effect on cotton pellet granuloma formation[1] |
| Synonyms | 奥沙西罗, N-Acetyl-L-hydroxyproline, N-乙酰-L-4-羟基脯氨酸 |
| molecular weight | 173.17 |
| Molecular formula | C7H11NO4 |
| CAS | 33996-33-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 100 mg/mL (577.47 mM) |
| References | 1. Ionac M , Parnham M J , Plauchithiu M , et al. OXACEPROL, AN ATYPICAL INHIBITOR OF INFLAMMATION AND JOINT DAMAGE[J]. pharmacological research, 1996, 33(6):367-373. 2. Herrmann G , Steeger D , Klasser M , et al. Oxaceprol is a Well-Tolerated Therapy for Osteoarthritis with Efficacy Equivalent to Diclofenac[J]. Clinical Rheumatology, 2000, 19(2):99-104. |